Corton Capital Inc. Nurix Therapeutics, Inc. Transaction History

Corton Capital Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$7.77 - $15.66 $96,954 - $195,405	-12,478 Reduced 31.31%	27,375 $402,000
Q4 2023 Feb 14, 2024	BUY	$4.25 - $10.71 $56,478 - $142,325	13,289 Added 50.03%	39,853 $411,000
Q3 2023 Nov 14, 2023	SELL	$7.86 - $10.08 $8,245 - $10,573	-1,049 Reduced 3.8%	26,564 $208,000
Q2 2023 Aug 14, 2023	BUY	$8.7 - $13.28 $240,233 - $366,700	27,613 New	27,613 $275,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.03B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Corton Capital Inc. with notifications on news.